Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
et al., Clinical Infectious Diseases, doi:10.1093/cid/ciab591 (date from earlier preprint) (meta analysis)
This is a severely flawed meta analysis. An open letter signed
by 40 physicians detailing errors and flaws, and requesting retraction, can
be found at [trialsitenews.com].
See also [bird-group.org].
Authors cherry-pick to include only 4 studies reporting
non-zero mortality and they initially claimed a mortality RR of 1.11
[0.16-7.65]. However, they reported incorrect values for Niaee et al.,
claiming an RR of 6.51 [2.18-19.45], when the correct RR for Niaee et al. is
0.18 [0.06-0.55]. After correction, their cherry-picked studies show >60%
mortality reduction, however authors did not correct the conclusion.
Similarly, for viral clearance and NCT04392713 (history), they report
20/41 treatment, 18/45 control, whereas the correct day 7 clearance numbers
are 37/41 and 20/45 (sum of clearance @72hrs and @7 days), or 17/41 and
2/45 @72 hrs.
The duration of hospital stay for Niaee et al. is also
incorrectly reported, showing a lower duration for the control group.
All of the errors are in one direction - incorrectly reporting
lower than actual efficacy for ivermectin. Authors claim to include all RCTs
excluding prophylaxis, however they only include 10 of the 24 non-prophylaxis
RCTs (28 including prophylaxis at the time of publication). Authors actually
reference meta analyses that do include the missing RCTs, so they should be
aware of the missing RCTs.
The PubMed search strategy provided is syntactically incorrect.
For additional errors, see [pubpeer.com]. Also
see [roundingtheearth.substack.com].
The authors state that they have no conflicts of interest on
medRxiv, however Dr. Pasupuleti’s affiliation is Cello Health, whose website
[cellohealth.com] notes that they provide services such as
“brand and portfolio commercial strategy for biotech and pharma”, and
that their clients are "24 of the top 25 pharmaceutical
companies”.
Only one of these errors has been partially fixed as of 5/29 -
the Niaee RR was corrected, but the associated conclusion was not. Other
errors have not been corrected. Comments on this article appear to be
censored, with zero comments posted as of July 5.
Currently there are
92 ivermectin
for COVID-19 studies, showing 51% [36‑62%] lower mortality, 31% [15‑45%] lower ventilation, 45% [22‑61%] lower ICU admission, 33% [20‑44%] lower hospitalization, and 78% [67‑86%] lower cases.
Roman et al., 28 Jun 2021, peer-reviewed, 6 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.